Umbilical Cord–Derived Mesenchymal Stem Cell (UC-MSC) Therapy for Premature Ovarian Insufficiency

Premature Ovarian Insufficiency (POI) is a condition where ovarian function declines before the age of 40, leading to infertility, hormonal imbalance, and early menopause. Affecting around 1% of women, it is marked by amenorrhea, elevated FSH, and low estrogen levels. Conventional treatments, such as hormone replacement therapy (HRT), can temporarily alleviate symptoms but fail to restore fertility or regenerate ovarian tissue.

Recent regenerative medicine breakthroughs using human umbilical cord–derived mesenchymal stem cells (UC-MSC stem cells) offer a new therapeutic path to restore ovarian activity and fertility naturally. This landmark clinical trial from the Chinese Academy of Sciences and Guangzhou Medical University demonstrates how UC-MSC transplantationcan rejuvenate ovarian function and improve pregnancy outcomes in women with POI.

Study Design and Methodology

The clinical study enrolled 61 women aged ≤35 years diagnosed with POI based on European Society of Human Reproduction and Embryology (ESHRE) criteria. UC-MSCs were isolated from healthy full-term umbilical cords under GMP conditions, characterized for purity (CD73⁺, CD90⁺, CD105⁺ markers), and confirmed to lack immune-reactive markers (CD34⁻, CD45⁻, HLA-DR⁻).

Patients received ultrasound-guided intra-ovarian injections of 0.5×10⁷ to 1×10⁷ UC-MSCs per ovary. Follow-ups at 1–6 months monitored follicular development, hormone profiles, and reproductive outcomes.

Key Results

1. Restoration of Ovarian Function

• 31% of patients developed mature follicles after the first UC-MSC injection.
• Antral follicle count (AFC), dominant follicle count (DFC), and anti-Müllerian hormone (AMH) levelssignificantly increased during the 6-month follow-up.
• Patients with shorter amenorrhea duration (<1 year) showed the highest response rate (70% achieved follicular development).

2. Successful Pregnancies and Live Births

• Four pregnancies were achieved post-treatment, resulting in healthy live births without genetic abnormalities or developmental defects.
• Microsatellite DNA testing confirmed that offspring were genetically related to the mothers, not the stem cell donors, proving UC-MSC stem cells act through regeneration rather than genetic replacement.

3. Predictive Factors for Success

• Shorter amenorrhea duration and presence of pre-treatment antral follicles strongly correlated with positive outcomes.
• Logistic regression confirmed pre-operative AFC as an independent predictor of successful follicular recovery (p < 0.01).

4. Safety and Tolerability

No serious adverse effects occurred. Minor, transient events (e.g., mild bleeding or temporary liver enzyme elevation) resolved spontaneously.
These findings establish UC-MSC stem cells therapy as safe, well-tolerated, and ethically viable for reproductive restoration.

Mechanisms of Action

UC-MSC stem cells restore ovarian function through multiple paracrine and immunoregulatory pathways:

1. Growth Factor Secretion:
   UC-MSCs release VEGF, FGF-2, IGF-1, EGF, and HGF, which improve vascularization, promote granulosa-cell proliferation, and reduce apoptosis.
2. Anti-Fibrotic Action:
   UC-MSC stem cells regulate fibrosis-related cytokines (MMPs, TIMPs, and TGF-β1), preventing scar formation and enhancing ovarian tissue elasticity.
3. Anti-Inflammatory Modulation:
   MSC stem cells upregulate T-regulatory (Treg) cells and down-regulate Th17 pro-inflammatory cells, restoring immune balance.
   Elevated IDO and PGE2 secretion further suppress macrophage and dendritic-cell activity, creating a regenerative microenvironment.
4. Follicular Activation and Anti-Aging Effects:
   Through PI3K-AKT signaling, UC-MSC stem cells may activate dormant follicles and counteract oxidative stress in ovarian stromal cells.

Clinical Implications

This trial provides robust evidence that UC-MSC stem cells therapy can partially reverse ovarian failure, restore menstrual cycles, and potentially re-establish fertility in women with POI. Compared to HRT, UC-MSC therapy targets the root cause tissue degeneration and cellular senescence rather than symptom relief.

Advantages of UC-MSC Treatment

• Ethically safe source: Derived from post-birth umbilical cords, non-embryonic.
• Low immunogenicity: Can be used allogenically without rejection.
• Long-term benefits: Promotes sustained ovarian regeneration and hormone balance.
• Holistic improvement: Enhances bone and cardiovascular health by restoring estrogen naturally.

Limitations and Future Directions

The authors note several challenges:

• Need for long-term follow-up to determine the duration of restored fertility.
• Optimization of UC-MSC stem cells dosage and injection frequency.
• Identification of ideal patient profiles (shorter amenorrhea, residual follicle presence).
• Expansion into multi-center, randomized clinical trials to confirm reproducibility.

Future research may also explore UC-MSC-derived exosomes as a cell-free therapeutic alternative, offering easier scalability and regulatory approval for regenerative fertility treatments.

Conclusion

This clinical analysis strongly supports the efficacy and safety of UC-MSC stem cells therapy for Premature Ovarian Insufficiency, providing new hope for women facing infertility due to early ovarian failure. The ability of UC-MSC stem cells to stimulate follicular regeneration, rebalance hormones, and enable pregnancy highlights their revolutionary potential in reproductive medicine.

SEO Keywords

stem cell therapy for fertility, UC-MSC ovarian rejuvenation, premature ovarian insufficiency treatment, mesenchymal stem cells Bangkok, regenerative fertility therapy, ovarian stem cell therapy, stem cell pregnancy success, anti-aging ovarian regeneration, UC-MSC clinical trial, fertility restoration Thailand, regenerative medicine for women, hormone balance therapy, stem cell fertility clinic Bangkok.

Reference

Yan L. et al. (2020). Clinical Analysis of Human Umbilical Cord Mesenchymal Stem Cell Allotransplantation in Patients with Premature Ovarian Insufficiency. Cell Proliferation, 53:e12938. DOI: 10.1111/cpr.12938.